P2RY12 and type 2 diabetes mellitus: Molecular therapy is a promising potent solution to T2DM since the P2Y12 shRNA treatment in T2DM rats mitigated a P2Y12 receptor expression at the mRNA level significantly; increased postganglionic sympathetic nerve discharge (SND); normalised FBG and FINS; improved insulin resistance, triglyceride (TG) levels, total cholesterol (TC) levels, and hepatic glycogen; and reduced NLRP3 complex expression.